Unsealed source therapy of painful bone metastases: An update

Seminars in Nuclear Medicine

Volumn 27, Issue 2, 1997, Pages 165-182

  McEwan, A J B ^a  

^a CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ETIDRONIC ACID RE 186; LEXIDRONAM SAMARIUM SM 153; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PENTETIC ACID; PHOSPHORUS 32; RADIOPHARMACEUTICAL AGENT; STRONTIUM 89; TIN;

BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DOSIMETRY; DRUG DISTRIBUTION; DRUG METABOLISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 0030935718     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-2998(97)80046-3     Document Type: Article

References (127)

1. Stoll BA Natural history, prognosis, and staging of bone metastases Stoll BA Parbhoos S Bone Metastases: Monitoring and Treatment 1983 Raven New York, NY 1 20
2. Daut RL Cleeland CS The prevalence and severity of pain in cancer Cancer 50 1982 1913 1918
3. Stjernswärd J Cancer pain relief: An important global health issue Clin J Pain 1 1985 95 97
4. World Health Organization Cancer Pain Relief 1986 World Health Organization Geneva
5. 32 labeled condensed phosphate J Nucl Med 1 1960 1 13
6. Treadwell AdeG Low-Beer BVA Friedell HL Metabolic studies on neoplasm of bone with the aid of radioactive strontium Am J Med Sci 204 1942 521 530
7. Pecher C Biological investigations with radioactive calcium and strontium: Preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer University of California Publications in Pharmacology 2 1942 117 149
8. 89) Ann Intern Med 33 1950 41 55
9. Kim SI Chen DCP Muggia FM A new look at radionuclides therapy in metastatic disease of bone (Review and prospects) Anticancer Res 8 1988 681 684
10. Mauch PM Drew MA Treatment of metastatic cancer to bone DeVita VT Jr Hellman S Rosenberg SA Cancer, Principles & Practice of Oncology 1985 Lippincott Philadelphia, PA 2132 2141
11. Nielsen OS Munro AJ Tannock IF Bone metastases: Pathophysiology and management policy J Clin Oncol 9 1991 509 524
12. Fidler IJ Radinsky R Genetic control of cancer metastasis J Natl Cancer Inst 82 1990 166 168
13. Fidler IJ Hart IR Biological diversity in metastatic neoplasms: origins and implications Science 217 1982 998 1003
14. Paterson AHG Bone metastases in breast cancer, prostate cancer and myeloma Bone 8 Suppl 1 1987 17 22
15. Campa JA Payne R The management of intractable bone pain: A clinician's perspective Semin Nucl Med 22 1992 3 10
16. Foley K Pain syndromes in patients with cancer Med Clin North Am 71 1987 169 184
17. Bonica JJ Treatment of cancer pain: Current status and future needs Fields HL Advances in Pain Research and Therapy vol 9 1985 Raven New York, NY 589 616
18. Cleeland CS The impact of pain on patients with cancer Cancer 54 1984 35 41
19. Twycross RG Lack SA Symptom Control in Far Advanced Cancer: Pain Relief 1983 Pitman Books London
20. Quirijnen JMSP Han SH Zonnenberg BA Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain J Nucl Med 37 1996 1511 1515
21. Inturrisi CE Hanks G Opioid analgesic therapy Doyle D Hans GWC MacDonald N Oxford Textbook of Palliative Medicine 1993 Oxford Oxford, UK 166 182
22. Portenoy RK Adjuvant analgesics in pain management Doyle D Hans GWC MacDonald N Oxford Textbook of Palliative Medicine 1993 Oxford Oxford, UK 187 203
23. Chisholm GD Carcinoma of the prostate: Reasons for endocrine treatment prior to symptomatic metastases Schroder FH Treatment of Prostatic Cancer: Facts and Controversies Progress in Clinical and Biological Research vol 359 1990 Wiley-Liss New York 1 6
24. Lippman ME Lichter AS Danforth DN Diagnosis and Management of Breast Cancer 1988 Saunders Philadelphia, PA
25. Stoll BA Hormonal therapy—pain relief and recalification Stoll BA Parbhoo S Bone Metastases: Monitoring and Treatment 1983 Raven New York, NY 321 342
26. MacDonald N Principles governing the use of cancer chemotherapy in palliative medicine Doyle D Hans GWC MacDonald N Oxford Textbook of Palliative Medicine 1993 Oxford Oxford, UK 105 115
27. Galasko CSB Orthopaedic principles and management Doyle D Hans GWC MacDonald N Oxford Textbook of Palliative Medicine 1993 Oxford Oxford, UK 274 281
28. Kuttig H Radiotherapy of cancer pain. Recent Results Cancer Res 89 1984 190 194
29. Hoskin PJ Scientific and clinical aspects of radiotherapy in the relief of bone pain Cancer Surv 7 1988 69 86
30. Hoskin PJ Radiotherapy in symptom management Doyle D Hans GWC MacDonald N Oxford Textbook of Palliative Medicine 1993 Oxford Oxford, UK 117 129
31. Bates T A review of local radiotherapy in the treatment of bone metastases and cord compression Int J Radiat Oncol Biol Phys 23 1992 217 221
32. Tong D Gillick L Hendrickson FR The palliation of symptomatic osseous metastases. Final results of the Radiation Therapy Oncology Group Cancer 50 1982 893 899
33. Madsen EL Painful bone metastasis: Efficacy of radiotherapy assessed by the patients: A randomised trial comparing 4 Gy × 6 versus 10 Gy × 2 Int J Radiat Oncol Biol Phys 9 1983 1775 1779
34. Price P Hoskin PJ Easton D Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases Radiother Oncol 6 1986 247 255
35. Price P Hoskin PJ Easton D Low dose single fraction radiotherapy in the treatment of metastatic bone pain: A pilot study Radiother Oncol 12 1988 297 300
36. Cole DJ A randomised trial of a single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastases Clin Oncol 1 1989 59 62
37. Fitzpatrick PJ Rider WD Half body radiotherapy Int J Radiat Oncol Biol Phys 1 1976 197 207
38. Qasim MM Half body irradiation in metastatic carcinomas Clin Radiol 32 1981 214 219
39. Salazar OM Rubin P Hendrickson FR Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors: Final radiation therapy oncology group report Cancer 58 1986 29 36
40. Winston MA Radioisotope therapy in bone and joint disease Semin Nucl Med 2 1979 114 119
41. 186Re-HEDP as bone therapeutic radiopharmaceuticals Nucl Med Biol 14 1987 223 232
42. (suppl) Holmes RA Radiopharmaceuticals in clinical trials Semin Oncol 20 1993 22 26
43. McEwan AJB Pain palliation and nuclear medicine Eur J Nucl Med 20 1993 1 3
44. Porzsolt F Tannock I Goals of palliative cancer therapy J Clin Oncol 11 1993 378 381
45. Logan KW Volkert WA Holmes RA Radiation dose calculations in persons receiving injection of samarium-153 EDTMR J Nucl Med 28 1987 505 509
46. Blake GM Zivanovic MA Blaquiere RM Strontium-89 therapy: Measurement of absorbed dose to skeletal metastases J Nucl Med 29 1988 549 557
47. Mertens WC Stitt L Porter AT Strontium-89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: A dose response relationship Am J Clin Oncol 16 1993 238 242
48. International Commission on Radiological Protection Publication 30. Metabolic Data for Strontium: Limits for Intakes of Radionuclides by Workers, Part 1 1979 Pergamon Oxford, U.K. 77 78
49. Blake GM Zivanovic MA McEwan AJ Strontium-89 therapy: Strontium kinetics and dosimetry in two patients treated for metastasising osteosarcoma Br J Rad 60 1987 253 259
50. 89Sr radionuclide therapy: Dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma Eur J Nucl Med 13 1987 41 46
51. Blake GM Gray JM Zivanovic MA Strontium-89 radionuclide therapy: A dosimetric study using impulse response function analysis Br J Rad 60 1987 685 692
52. Blake GM Zivanovic MA Blaquiere RM Strontium-89 therapy: Measurement of absorbed dose to skeletal metastases J Nucl Med 29 1988 549 557
53. Blake GM Zivanovic MA McEwan AJ Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate Eur J Nucl Med 12 1986 447 454
54. 89Sr therapy: Strontium plasma clearance in disseminated prostatic carcinoma Eur J Nucl Med 15 1989 49 54
55. 89Sr radionuclide therapy Eur J Nucl Med 15 1989 780 783
56. Breen SL Powe JE Porter AT Dose estimation of Strontium-89 radiotherapy of metastatic prostatic carcinoma J Nucl Med 33 1992 1316 1323
57. Mathieu L Chevalier P Galy G Preparation of 186-Rhenium labelled HEDP and its possible use in the treatment of osseous neoplasms Int J Appl Radiat Isot 30 1979 725 727
58. Deutsch E Libson K Vanderheyden JL The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine Int J Nucl Med Biol 13 1986 465 477
59. Maxon HR Thomas SR Hertzberg VS Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases Semin Nucl Med 22 1992 33 40
60. Maxon HR Deutsch EA Thomas SR Re-186(Sn)HEDP for treatment of multiple metastatic foci in bone: Human biodistribution and dosimetric studies Radiology 166 1988 501 507
61. de Klerk JMH van Dijk A van het Schip AD Pharmacokinetics of Rhenium-186 after administration of Rhenium-186-HEDP to patients with bone metastases J Nucl Med 33 1992 646 651
62. Samaratunga RC Thomas SR Hinnefeld JD A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from Rhenium-186(Sn)-HEDP J Nucl Med 36 1995 336 350
63. Goeckeler WF Edwards B Volkert WA Skeletal localization of Samarium-153 chelates: Potential therapeutic bone agents J Nucl Med 28 1987 495 504
64. Singh A Holmes RA Farhangi M Human pharmacokinetics of Samarium-153 EDTMP in metastatic cancer 30 1989 1814 1818
65. Heggie JCP Radiation absorbed dose calculations for Samarium-153-EDTMP localized in bone J Nucl Med 32 1991 840 844
66. Eary JF Collins C Stabin M Samarium-153-EDTMP biodistribution and dosimetry estimation J Nucl Med 34 1993 1031 1036
67. International Commission on Radiological Protection Publication 53. Radiation Dose to Patients from Radiopharmaceuticals 1988 Pergamon Oxford, UK 84
68. Low-Beer BVA Blais RS Scofield NE Estimation of dosage for intravenously administered P-32 AJR 67 1952 28 41
69. 32P Br J Radiol 49 1976 133 140
70. Silberstein EB Elgazzar AH Kapilivsky A Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases Semin Nucl Med 22 1992 17 27
71. Friedell HL Storaasli JP The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to the bone AJR 64 1950 559 575
72. Max MB Portenoy RK Pain research: Designing clinical trials in palliative care Doyle D Hans GWC MacDonald N Oxford Textbook of Palliative Medicine 1993 Oxford Oxford, UK 77 86
73. Schmidt CG Firusian N 89-Sr for the treatment of incurable pain in patient with neoplastic osseous infiltrations Int J Clin Pharmacol Res 9 1974 199 205
74. 89Strontium therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: A preliminary report J Urol 16 1976 764 768
75. Firusian N Endoossale isotopen-therapie maligner skeleterkrankungen Z. Krebsforsch 91 1978 143 156
76. Kutzner J Grimm W Hahn K Palliative strahlentherapie mit Strontium-89 bei ausgedehnter skelettmetastasierung Strahlentherapie 154 1978 317 322
77. Hayek D Ritschard J Zwahlen A Emploi du strontium-89 dans le traitement antalgique des métastases osseuses Schwiez med Wschr 110 1980 1154 1159
78. Correns H-J Mebel M Buchali K Strontium 89 therapy of bone metastases of carcinoma of the prostate gland Eur J Nucl Med 4 1979 33 35
79. Kimmig B Hermann HJ Kober B Nuklearmedizinishe Rötgenblätter 36 1983 216 219
80. Buchali K Correns HJ Schnorr D 89-Strontium-Therapy of skeletal metastases of prostatic carcinoma Proceedings of the 1984 Bad Gastein International Radiopharmaceutical Conference 1984 151 156
81. Silberstein EB Williams C Strontium-89 therapy for the pain of osseous metastases J Nucl Med 26 1985 345 348
82. Laing AH Ackery DM Bayly RJ Strontium-89 chloride for pain palliation in prostatic skeletal malignancy Br J Rad 64 1991 816 822
83. Lewington VJ McEwan AJ Ackery DM A prospective, randomised double-blind crossover study to examine the efficacy of Strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone Eur J Cancer 27 1991 954 958
84. Robinson RG Preston DF Schiefelbein M Strontium-89 therapy for the palliation of pain due to osseous metastases JAMA 274 1995 420 424
85. Porter AT McEwan AJB Powe JE Results of a randomized phase-III trial to evaluate the efficacy of Strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer Int J Radiat Oncol Biol Phys 25 1993 805 813
86. 89Sr-chloride) in patients with prostate cancer metastatic to bone Nucl Med Commun 15 1994 499 504
87. Quilty PM Kirk D Bolger JJ A comparison of the palliative effects of Strontium-89 and external beam radiotherapy in metastatic prostate cancer Radiother Oncol 31 1994 33 40
88. Dearnaley DP Bayly RJ A'Hern RP Palliation of bone metastases in prostate cancer. Hemibody irradiation or Strontium-89 Clin Oncol 4 1992 101 107
89. Mertens WC Porter AT Reid RH Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: A preliminary report J Nuc Med 33 1992 1437 1443
90. Mertens WC Radionuclide therapy of bone metastases: Prospects for enhancement of therapeutic efficacy Semin Oncol 20 1993 49 55 suppl 2
91. Sciuto R Maini CL Tofani A Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with Strontium-89 Nucl Med Commun 17 1996 799 804
92. Hansen DV Holmes ER Catton G Strontium-89 therapy for painful osseous metastatic prostate and breast cancer Am Fam Physician 47 1993 1795 1800
93. Berna L Carrio I Alonso C Bone pain palliation with Strontium-89 in breast cancer patients with bone metastases and refractory bone pain Eur J Nucl Med 22 1995 1101 1104
94. Reddy EK Robinson RG Mansfield CM Strontium 89 for palliation of bone metastases J Nat Med Assoc 78 1986 27 32
95. Kloiber R Molnar CP Barnes M Sr-89 therapy for metastatic bone disease: Scintigraphic and radiographic follow-up Radiology 163 1987 719 723
96. Robinson RG Spicer JA Preston DF Treatment of metastatic bone pain with Strontium-89 Nucl Med Biol 14 1987 219 222
97. Tennvall J Darte L Lundgren R Palliation of multiple bone metastases from prostatic carcinoma with Strontium-89 Acta Oncol 27 1988 365 369
98. Buchali K Correns H-J Schuerer M Results of a double blind study of 89-Strontium therapy of skeletal metastases of prostatic carcinoma Eur J Nucl Med 14 1988 349 351
99. McEwan AJB Porter AT Venner PM An evaluation of the safety and efficacy of treatment with Strontium-89 in patients who have previously received wide field radiotherapy Antibody, Immunoconjugates, and Radiopharmaceuticals 3 1990 91 97
100. 89Strontium in bone metastases from hormone resistant prostate cancer: Palliation effect and biochemical changes Br J Cancer 66 1992 177 180
101. Guerrieri P Modoni S Parisi S Bone formation markers and pain palliation in bone metastases treated with Strontium-89 Am J Clin Oncol 17 1994 77 79
102. Kovner F Ron IG Levita M Strontium-89 therapy in a patient with carcinoma of unknown origin and incurable pain from bone metastases J Pain Symptom Manage 8 1993 47 51
103. Maxon HR Schroder LE Hertzberg VS Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: Results of a double-blind crossover comparison with placebo J Nucl Med 32 1991 1877 1881
104. Maxon HR Schroder LE Thomas SR Re-186(Sn)HEDP for treatment of painful osseous metastases: Initial clinical experience in 20 patients with hormone-resistant prostate cancer Radiology 176 1990 155 159
105. Englaro EE Schroder LE Thomas SR Safety and efficacy of repeated sequential administration of Re-186(Snl) HEDP as palliative therapy for painful skeletal metastases. Initial case reports of two patients Clin Nucl Med 17 1992 41 44
106. de Klerk JMH Zonnenberg BA van het Schip AD Dose escalation study of Rhenium-186 Hydroxyethylidene Diposphonate in patients with metastatic prostate cancer Eur J Nucl Med 21 1994 1114 1120
107. de Klerk JMH van het Schip AD Zonnenberg BA Evaluation of thrombocytopenia in patients treated with Rhenium-186-HEDP: Guidelines for individual dosage recommendations J Nucl Med 35 1994 1423 1428
108. Turner JH Claringbold PG Hetherington EL A Phase I study of Samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases J Clin Oncol 7 1989 1926 1931
109. Turner JH Claringbold: A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose Samarium-153 Ethylenediaminetetramethylene Phosphonate Eur J Cancer 27 1991 1084 1086
110. Collins C Eary JF Donaldson G Samarium-153-EDTMP in bone metastases of hormone refractory prostate Carcinoma: A phase I/II trial J Nucl Med 34 1993 1839 1844
111. Sandeman TF Budd RS Martin JJ Samarium-153-Labelled EDTMP for bone metastases from cancer of the prostate Clin Oncol 4 1992 160 164
112. Farhanghi M Holmes RA Volker WA Samarium-153-EDTMP: Pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer J Nucl Med 33 1992 1451 1458
113. Atkins HL Mausner LF Srivastava SC Biodistribution of Sn-117m (4+) DTPA for palliative therapy of painful osseous metastases Radiology 186 1993 279 283
114. Maxfield JR Maxfield JGS Maxfield WS The use of radioactive phosphorus and testosterone in metastatic bone lesions from breast and prostate South Med J 51 1958 320 328
115. (abstract) Hertz S Modifying effect of steroid hormone therapy of human neoplastic disease as judged by radioactive phosphorus (P-32) studies J Clin Invest 29 1950 821
116. Fowler JE Whitmore WF Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer Cancer 49 1982 1373 1377
117. Corwin SH Malament M Small M Experiences with P-32 in advanced carcinoma of the prostate J Urol 104 1970 745 748
118. Tong ECK Rubenfeld S The treatment of bone metastases with parathormone followed by radiophosphorus Am J Radiol 99 1967 422 434
119. 89Sr compared with external beam and hemibody irradiation: A historical perspective Cancer Invest 7 1989 139 160
120. Cowan RJ Chilton HM Cooper MR Hematologic depression following therapy with Strontium-89 Chloride Clin Nucl Med 11 1986 845 846
121. Leong C McKenzie MR Coupland DB Disseminated intravascular coagulation in a patient with metastatic prostate cancer: Fatal outcome following Strontium-89 therapy J Nucl Med 35 1994 1623 1664
122. Burgess NA Hudd C Rees RWM Haemostatic pitfalls in advanced prostatic cancer Br J Urol 71 1993 231 233
123. Adamson AS Witherow RO'N Francis JL Coagulopathy in the prostate cancer patient: Prevalence and clinical relevance Ann R Coll Surg Engl 75 1993 1001 1004
124. (correspondence) Amdur R Eaton W Mitchell S The Sr-89 bracelet Int J Radiation Oncol Biol Physics 32 1995 897
125. Breitbard W Passik SD Psychological and psychiatric interventions in pain control Doyle D Hans GWC MacDonald N Oxford Textbook of Palliative Medicine 1993 Oxford Oxford, UK 244 256
126. Isco N Williams JI Szalai JP Prediction of psychosocial distress in patients with cancer Osoba D Effect of Cancer on Quality of Life 1991 CRC Press Boca Raton, FL 41 57
127. Osoba D Rationale for the timing of health-related quality-of-life (HQL) assessments in oncological palliative therapy Cancer Treat Rev 22 suppl A 1996 69 73